Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
about
Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutantKASL clinical practice guidelines: management of chronic hepatitis BThe Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsDetection and analysis of resistance mutations of hepatitis B virusAntiviral drug resistance: mechanisms and clinical implicationsAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsStable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B VirusTwo-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.Antiviral therapy and resistance with hepatitis B virus infection.Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Antiviral drug resistance as an adaptive processComplex dynamics of hepatitis B virus resistance to adefovir.Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibilityLow-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.The role of entecavir in the treatment of chronic hepatitis B.New approaches in the management of chronic hepatitis B: role of tenofovir.European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypesHBV and HCV therapy.Emerging drugs for hepatitis B.Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient.Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia.Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.Future prospectives for the management of chronic hepatitis B.Management of chronic hepatitis B: consensus guidelinesAntiviral-resistant hepatitis B virus: can we prevent this monster from growing?Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Antiviral resistance and hepatitis B therapy.Resistance issues in treating chronic hepatitis B.Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.Pathobiology of HBV mutants and clinical impact for treatment monitoring.Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries.Tenofovir for the treatment of hepatitis B virus.Management of Antiviral Resistance in Chronic Hepatitis B.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.
P2860
Q25256648-6400ADDA-A69A-4E69-87A5-759792531664Q26752475-12C64052-5941-4B80-B60D-F977EB23CECDQ26781795-B757F04A-ECA3-40A8-BD75-4A9A8D608547Q28266666-2A36FADA-9556-419C-8FDA-391582F61BDBQ28282376-E0D2F1B4-954A-41F0-BD54-E04B6153141BQ28535003-4232411A-3504-4D99-AF73-C554C3349164Q28551711-E5953720-5CA8-4208-8349-A1B127DB0D5CQ33267067-1BAFBA70-EA96-4816-91A0-855704FE2138Q33417353-D562A62E-9122-4C2C-9B22-F2E049C8AF53Q33787531-9D74B3E1-A195-43D5-BFFA-CFF33909F688Q33826784-BC7B440C-93C4-4DEB-B059-7925463EAC04Q33878407-5A611093-44B5-4068-A68E-549BEA5CE419Q34208672-C884F885-440F-4ABB-8880-7CD7B02DC616Q34366437-37852FFB-B80F-4B1B-B123-1A340EC829AEQ34382099-7CC4B685-481D-4BD4-A891-F0E107620E7AQ34409132-EEB87B97-BB72-497C-8B12-1C725D1DE203Q34592640-1AAB273D-39E1-4105-AF8D-3C6450764E2BQ35026531-10C61AE7-81D9-48BD-B012-9370E60DBFF2Q35073136-519D9A41-7426-4DBA-BE68-BCCF66771530Q35259824-DBEA449B-6341-401A-9946-87F292C4AA68Q35359369-4ABCCA54-1781-44D9-B769-1D62C8F0EF8EQ35724618-79FF6602-BF05-4908-B48E-2DDFD7962169Q35975629-12CC005D-0952-4574-8C07-8DA26290CA63Q36757579-9458F28E-E379-4C8C-AC91-959808EEDA3AQ36841719-FBBE0618-432D-4AD7-A0C8-A00A8CB0818AQ36849343-2C569868-7650-40BE-ADF0-E9DB5200F656Q36980718-FA109F82-F10C-4E33-8987-F827E931047EQ37220899-893434A0-C426-44F8-82BA-81D165C417F1Q37229851-1DC768E3-F104-4F83-9136-86AC310B57B9Q37255008-B5DE431E-0F80-426A-916A-1167A63A7A88Q37277073-7B2404CD-C612-42DB-BEB5-E544E4D40629Q37335661-BDCDE42B-501B-4796-ACC8-FB075FD9AC3BQ37432098-E36DCF58-2B48-4C94-8672-8FC26DD47375Q37465040-24092BD4-36A7-4759-BC88-5991B4E70698Q37508051-61F74B23-7BF2-4176-A8EB-913720EED3A4Q37605886-1185B0CB-E88A-4387-9E13-CA0335CAD7A1Q37696029-2D1A0963-FF1A-46E4-B1E3-E5D6F4FF5776Q37760897-1AACA9E3-B2CD-4F9D-8A5A-F2B407A68636Q37762114-8AD2D3B5-CD8A-4605-9CC4-AB42D7239C56Q37768591-BDF774C5-8D08-4FFE-9CB0-21C7A03A1586
P2860
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Susceptibility to antivirals o ...... both lamivudine and adefovir.
@en
type
label
Susceptibility to antivirals o ...... both lamivudine and adefovir.
@en
prefLabel
Susceptibility to antivirals o ...... both lamivudine and adefovir.
@en
P2093
P356
P1433
P1476
Susceptibility to antivirals o ...... o both lamivudine and adefovir
@en
P2093
Anne-Carole Jacquard
Christian Pichoud
Christian Trépo
Jean-Pierre Villeneuve
Marie-Noëlle Brunelle
Sandra Carrouée-Durantel
P304
P356
10.1002/HEP.20723
P407
P577
2005-06-01T00:00:00Z